The latest price target for Verrica Pharmaceuticals (NASDAQ:VRCA) was reported by HC Wainwright & Co. on November 6, 2024. The analyst firm set a price target for $0.00 expecting VRCA to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Verrica Pharmaceuticals (NASDAQ:VRCA) was provided by HC Wainwright & Co., and Verrica Pharmaceuticals downgraded their neutral rating.

The last upgrade for Verrica Pharmaceuticals Inc happened on July 25, 2023 when Needham raised their price target to $10. Needham previously had a hold for Verrica Pharmaceuticals Inc.

The last downgrade for Verrica Pharmaceuticals Inc happened on November 6, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Verrica Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verrica Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verrica Pharmaceuticals was filed on November 6, 2024 so you should expect the next rating to be made available sometime around November 6, 2025.

While ratings are subjective and will change, the latest Verrica Pharmaceuticals (VRCA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Verrica Pharmaceuticals (VRCA) is trading at is $0.92, which is out of the analyst’s predicted range.